Dinja Oosterhoff work email
- Valid
- Valid
Dinja Oosterhoff personal email
After >20 years developing cancer therapeutics and prophylactic vaccines for infectious diseases, Dinja created her own company, helping vaccine focused companies to develop new products. Dinja has a strong scientific background and extensive experience in developing vaccines from concept to Phase I/II clinical studied. She has a big track record in successfully maturing vaccine concepts from idea to First in Human. On top, Dinja is highly expertised in securing non-dilutive funding for development of vaccine concepts.Services: Scientific strategy, translational science, fundraising, product development, program managementSpecialties: Vaccines, Immunotherapy, Infectious Diseases, Dendritic Cells, Oncology, Cell and Gene Therapy
Dyna Consultancy
-
Founder And PresidentDyna Consultancy Jun 2024 - Present
-
Vice President R&DIntravacc Nov 2022 - May 2024Bilthoven, Utrecht, Nl -
Director Translational Research And InnovationIntravacc Jan 2022 - Nov 2022Bilthoven, Utrecht, Nl
-
Program DirectorIntravacc Oct 2020 - Dec 2021Bilthoven, Utrecht, Nl
-
Program Manager Viral VaccinesIntravacc Jun 2019 - Oct 2020Bilthoven, Utrecht, Nl
-
Project Lead And Scientist Viral Vaccine DevelopmentIntravacc Mar 2013 - Jun 2019Bilthoven, Utrecht, NlAt Intravacc I am working as scientist and project lead in several viral vaccine projects. In one of the projects we aim to develop an inactivated viral vaccines for non-polio enteroviruses, like EVA71 and CVA16 to prevent Hand-, Foot, Mouth- disease, whereas in another project the aim is to improve the viral producer cell line, Vero, to obtain increased viral output.
-
ScientistDcprime Sep 2010 - Dec 2012DCPrime develops the cell line DCOne as a vaccine for AML patients. DCOne progenitor cells can bedifferentiated into mature dendritic cells that can induce an immune response directed to AML proteins.My work at DCPrime aimed to broaden the applicability of the DCOne vaccine by loading the dendritic cells with tumor-derived peptides originating from several solid tumor types and optimize this process.
-
Post-DocVu Medisch Centrum Feb 2005 - Apr 2011Amsterdam, NlPost Doc at the Department of Medical Oncology, Division of Immunotherapy. Project: targeting and modulation of Dendritic Cells to overcome tumor-induced suppressionTumors suppress the development and function of dendritic cells through the release of suppressivefactors. This is an effective way for the tumor to escape immune control. In this project we focused onthe identification of the most important tumor-derived suppressive factors and their intracellularsignaling pathways. We have demonstrated that IL-10, secreted by tumor cells, is the most importantsuppressive factor, whereas the p38 MAPK signaling pathway appeared to be essential for the properdifferentiation of dendritic cells. This information can be used to develop vaccines that can simultaneously induce a potent anti-tumor immune response and overcome tumor-mediatedsuppression. -
Phd Student At The Department Of Medical OncologyVu University Medical Center Sep 1999 - Sep 2004Amsterdam, NlPhD student at the Division of Gene Therapy, thesis: Adenoviral gene therapy in combination with (tumor selective) chemotherapy for the treatment of cancerCPT-11 (Irinotecan) is a chemotherapeutic drug that needs to be converted into the active compound SN-38 in patients by the enzyme carboxylesterase. However, only 5% of the prodrug is activated in human patients, because of limited availability of the prodrug converting enzyme. In this PhD project the focus was on achieving tumor selective expression of a secreted or tumor targeted form of carboxylesterase by the use of adenoviral vectors in order to selectively activate the prodrug at the site of the tumor.
Dinja Oosterhoff Skills
Dinja Oosterhoff Education Details
-
Vrije Universiteit Amsterdam (Vu Amsterdam)Medical Biology -
Augustinus College
Frequently Asked Questions about Dinja Oosterhoff
What company does Dinja Oosterhoff work for?
Dinja Oosterhoff works for Dyna Consultancy
What is Dinja Oosterhoff's role at the current company?
Dinja Oosterhoff's current role is Senior Vaccine Development Executive.
What is Dinja Oosterhoff's email address?
Dinja Oosterhoff's email address is d.****@****vumc.nl
What schools did Dinja Oosterhoff attend?
Dinja Oosterhoff attended Vrije Universiteit Amsterdam (Vu Amsterdam), Augustinus College.
What skills is Dinja Oosterhoff known for?
Dinja Oosterhoff has skills like Cancer, Immunology, Cell Culture, Gene Therapy, Oncology, Molecular Biology, Cell Biology, Western Blotting, Cell, Immunohistochemistry, Virology, Elisa.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial